345
Participants
Start Date
March 1, 2021
Primary Completion Date
June 9, 2022
Study Completion Date
December 28, 2026
inclisiran sodium
Subcutaneously injected on Day 1, 90 and 270 (Core Part). Subcutaneously injected on Day 360 and every 6 months thereafter until EOS visit (Extension Part)
Placebo
Subcutaneously injected on Day 1, 90, and 270.
Novartis Investigative Site, Taipei
Novartis Investigative Site, Taipei
Novartis Investigative Site, Taipei
Novartis Investigative Site, Wŏnju
Novartis Investigative Site, Gwangju
Novartis Investigative Site, Kaohsiung City
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Singapore
Novartis Investigative Site, Changchun
Novartis Investigative Site, Singapore
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Zhujing
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Suzhou
Novartis Investigative Site, Xuzhou
Novartis Investigative Site, Nantong
Novartis Investigative Site, Jinan
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Xiamen
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Foshan
Novartis Investigative Site, Xian
Novartis Investigative Site, Lanzhou
Novartis Investigative Site, Baotou
Novartis Investigative Site, Hohhot
Novartis Investigative Site, Taiyuan
Novartis Investigative Site, Shijiazhuang
Novartis Investigative Site, Seoul
Novartis Investigative Site, Incheon
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY